154548-45-5

Usage

Uses

Used in Organic Synthesis:
4-OXO-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER 3-ETHYL ESTER is used as a building block in organic synthesis for the creation of various pharmaceutical compounds and other organic molecules. Its unique structure and functional groups make it a valuable intermediate in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 4-OXO-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER 3-ETHYL ESTER is used as a precursor for the development of new medicinal compounds. Its potential medicinal properties are being explored for various therapeutic applications, leveraging its chemical versatility to create novel drug candidates.
Used in Chemical Intermediates Industry:
4-OXO-PIPERIDINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER 3-ETHYL ESTER is used as a key intermediate in the production of specialty chemicals and fine chemicals. Its role in this industry is crucial for the synthesis of high-value compounds used in various applications, including but not limited to pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 4644-61-5 ethyl 4-piperidone-3-carboxylate hydrochloride 
• 501-53-1 benzyl chloroformate 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 

Downstream Products

• 852443-90-4 4-hydroxy-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester 
• 1207852-54-7 8-benzyl 6-ethyl 1,4-dithia-8-azaspiro[4.5]decane-6,8-dicarboxylate 

Relevant academic research and scientific papers

Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors

Novel series of 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylates (5a–p, 7, and 8a–e) were synthesized and evaluated for their antiproliferative activity against the A549, HT29, H460, and H1975 cancer cell lines in vitro. Nine compounds (5a–c, 5i, 5j, 7, 8a, 8b, 8i) demonstrated moderate to significant cytotoxic activity with IC50 values below 18 μM on A549 cells, which were comparable to that of the reference gefitinib (IC50 = 18.44 μM). Especially, the further enzymatic analysis on epidermal growth factor receptor (EGFR), HER2, and VEGFR identified compound 5a as a promising hit that exhibited considerable potency both in cellular (IC50 = 5.67, 17.04, 11.29, and 12.65 μM, respectively) and EGFR enzymatic assays (IC50 = 14.8 nM). Compound 5a was capable of down-regulating the expression of EGFR and inhibited EGFR phosphorylation in a dose-dependent manner, representing a potential EGFR candidate for further optimization.

Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations

A novel series of 4-arylamino-6/7-substituted-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines were designed, synthesized and their biological activities as the potential anti-proliferative agents and EGFR kinase inhibitors were evaluated. Both of N-acrylamide fragment in THPPs and 4-aniline groups with substituents played key roles for their significant anti-proliferative activities against four cancer cell lines (HT29, A549, H460 and H1975). Especially inhibitory activity of Gefitinib-resistant H1975 were showed more favorable, which could be observed from compounds 13b, 13c, 13n, 13o, 13p, 13r, 13s, 13u and 24c obviously. By evaluation of inhibiting EGFR and HER2 kinases, seven compounds (13b, 13g, 13n, 13o, 13p, 13r and 13s) showed stronger EGFR potency with IC50 ≤ 18 nM, which could also be understood by preliminary docking study of 13b with EGFR kinase. In view of the primary SAR, bisarylaniline derivatives (13o, 13p, 13r and 13s) showed obvious improvements on HER2 inhibition, which indicated their being potential EGFR/HER2 dual kinase inhibitors.

6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES

Compounds of formula (I): and their use in the inhibition of Trk activity are described.

Immunopotentiator agents

Novel compounds and methods for preparing same, immunopotentiating compositions, and a method for potentiating the immune system of a host animal. The method comprises administering to the animal an effective amount of an immunopotentiating compound of Formula I or Formula II, or a physiologically acceptable salt.